Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy

The aim of this study was to evaluate if bone marrow (BM) SUVmax measured on pre-treatment 18F-FDG PET/CT predicts the clinical outcome of locally advanced cervical cancer (LACC). We recruited retrospectively patients with LACC who underwent staging 18F-FDG PET/CT and had baseline blood tests, then...

Descripción completa

Detalles Bibliográficos
Autores principales: Seban, Romain-David, Robert, Charlotte, Dercle, Laurent, Yeh, Randy, Dunant, Ariane, Reuze, Sylvain, Schernberg, Antoine, Sun, Roger, Mignot, Fabien, Terroir, Marie, Schlumberger, Martin, Haie-Meder, Christine, Chargari, Cyrus, Deutsch, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492982/
https://www.ncbi.nlm.nih.gov/pubmed/31069132
http://dx.doi.org/10.1080/2162402X.2019.1574197
_version_ 1783415173494603776
author Seban, Romain-David
Robert, Charlotte
Dercle, Laurent
Yeh, Randy
Dunant, Ariane
Reuze, Sylvain
Schernberg, Antoine
Sun, Roger
Mignot, Fabien
Terroir, Marie
Schlumberger, Martin
Haie-Meder, Christine
Chargari, Cyrus
Deutsch, Eric
author_facet Seban, Romain-David
Robert, Charlotte
Dercle, Laurent
Yeh, Randy
Dunant, Ariane
Reuze, Sylvain
Schernberg, Antoine
Sun, Roger
Mignot, Fabien
Terroir, Marie
Schlumberger, Martin
Haie-Meder, Christine
Chargari, Cyrus
Deutsch, Eric
author_sort Seban, Romain-David
collection PubMed
description The aim of this study was to evaluate if bone marrow (BM) SUVmax measured on pre-treatment 18F-FDG PET/CT predicts the clinical outcome of locally advanced cervical cancer (LACC). We recruited retrospectively patients with LACC who underwent staging 18F-FDG PET/CT and had baseline blood tests, then treated by chemoradiation therapy (CRT), followed by image-guided adaptive brachytherapy (IGABT). BM SUVmax was calculated and correlated to inflammatory blood markers. Tumor size and pelvic lymph node involvement were evaluated on baseline MRI. Prognostic value of SUV uptake and blood markers regarding overall survival (OS), pelvic and extra-pelvic recurrence-free survival (PRFS and EPRFS respectively) was assessed using Cox models with adjusted p-values. 116 patients with FIGO stage Ib-IVa cervical cancer, treated between 2005 and 2014, were analyzed. The median follow-up was 75.5 months. BM SUVmax was significantly correlated to tumor SUVmax. In multivariate analysis, PRFS was significantly poorer in patients with high BM SUVmax (>2.8) and neutrophilia (p < .05). Tumor size (>5 vs ≤5 cm) could predict PRFS, EPRFS and OS (p < .05). In our cohort, FIGO stage (I-II vs III-IV), pelvic lymph node involvement and tumor SUVmax (>12 vs ≤12) were not prognostic for OS or pelvic and extra-pelvic relapses. Patients with LACC and high BM SUVmax on 18F-FDG PET have worse PFRS following CRT plus IGABT. These results can be potentially explained by the pro-inflammatory role of the tumor microenvironment and G-CSF expressed by tumor cells. These data support the role of PET as a potential indicator of disease aggressiveness beyond tumor staging.
format Online
Article
Text
id pubmed-6492982
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-64929822019-05-08 Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy Seban, Romain-David Robert, Charlotte Dercle, Laurent Yeh, Randy Dunant, Ariane Reuze, Sylvain Schernberg, Antoine Sun, Roger Mignot, Fabien Terroir, Marie Schlumberger, Martin Haie-Meder, Christine Chargari, Cyrus Deutsch, Eric Oncoimmunology Original Research The aim of this study was to evaluate if bone marrow (BM) SUVmax measured on pre-treatment 18F-FDG PET/CT predicts the clinical outcome of locally advanced cervical cancer (LACC). We recruited retrospectively patients with LACC who underwent staging 18F-FDG PET/CT and had baseline blood tests, then treated by chemoradiation therapy (CRT), followed by image-guided adaptive brachytherapy (IGABT). BM SUVmax was calculated and correlated to inflammatory blood markers. Tumor size and pelvic lymph node involvement were evaluated on baseline MRI. Prognostic value of SUV uptake and blood markers regarding overall survival (OS), pelvic and extra-pelvic recurrence-free survival (PRFS and EPRFS respectively) was assessed using Cox models with adjusted p-values. 116 patients with FIGO stage Ib-IVa cervical cancer, treated between 2005 and 2014, were analyzed. The median follow-up was 75.5 months. BM SUVmax was significantly correlated to tumor SUVmax. In multivariate analysis, PRFS was significantly poorer in patients with high BM SUVmax (>2.8) and neutrophilia (p < .05). Tumor size (>5 vs ≤5 cm) could predict PRFS, EPRFS and OS (p < .05). In our cohort, FIGO stage (I-II vs III-IV), pelvic lymph node involvement and tumor SUVmax (>12 vs ≤12) were not prognostic for OS or pelvic and extra-pelvic relapses. Patients with LACC and high BM SUVmax on 18F-FDG PET have worse PFRS following CRT plus IGABT. These results can be potentially explained by the pro-inflammatory role of the tumor microenvironment and G-CSF expressed by tumor cells. These data support the role of PET as a potential indicator of disease aggressiveness beyond tumor staging. Taylor & Francis 2019-03-06 /pmc/articles/PMC6492982/ /pubmed/31069132 http://dx.doi.org/10.1080/2162402X.2019.1574197 Text en © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Original Research
Seban, Romain-David
Robert, Charlotte
Dercle, Laurent
Yeh, Randy
Dunant, Ariane
Reuze, Sylvain
Schernberg, Antoine
Sun, Roger
Mignot, Fabien
Terroir, Marie
Schlumberger, Martin
Haie-Meder, Christine
Chargari, Cyrus
Deutsch, Eric
Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy
title Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy
title_full Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy
title_fullStr Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy
title_full_unstemmed Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy
title_short Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy
title_sort increased bone marrow suvmax on 18f-fdg pet is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492982/
https://www.ncbi.nlm.nih.gov/pubmed/31069132
http://dx.doi.org/10.1080/2162402X.2019.1574197
work_keys_str_mv AT sebanromaindavid increasedbonemarrowsuvmaxon18ffdgpetisassociatedwithhigherpelvictreatmentfailureinpatientswithcervicalcancertreatedbychemoradiotherapyandbrachytherapy
AT robertcharlotte increasedbonemarrowsuvmaxon18ffdgpetisassociatedwithhigherpelvictreatmentfailureinpatientswithcervicalcancertreatedbychemoradiotherapyandbrachytherapy
AT derclelaurent increasedbonemarrowsuvmaxon18ffdgpetisassociatedwithhigherpelvictreatmentfailureinpatientswithcervicalcancertreatedbychemoradiotherapyandbrachytherapy
AT yehrandy increasedbonemarrowsuvmaxon18ffdgpetisassociatedwithhigherpelvictreatmentfailureinpatientswithcervicalcancertreatedbychemoradiotherapyandbrachytherapy
AT dunantariane increasedbonemarrowsuvmaxon18ffdgpetisassociatedwithhigherpelvictreatmentfailureinpatientswithcervicalcancertreatedbychemoradiotherapyandbrachytherapy
AT reuzesylvain increasedbonemarrowsuvmaxon18ffdgpetisassociatedwithhigherpelvictreatmentfailureinpatientswithcervicalcancertreatedbychemoradiotherapyandbrachytherapy
AT schernbergantoine increasedbonemarrowsuvmaxon18ffdgpetisassociatedwithhigherpelvictreatmentfailureinpatientswithcervicalcancertreatedbychemoradiotherapyandbrachytherapy
AT sunroger increasedbonemarrowsuvmaxon18ffdgpetisassociatedwithhigherpelvictreatmentfailureinpatientswithcervicalcancertreatedbychemoradiotherapyandbrachytherapy
AT mignotfabien increasedbonemarrowsuvmaxon18ffdgpetisassociatedwithhigherpelvictreatmentfailureinpatientswithcervicalcancertreatedbychemoradiotherapyandbrachytherapy
AT terroirmarie increasedbonemarrowsuvmaxon18ffdgpetisassociatedwithhigherpelvictreatmentfailureinpatientswithcervicalcancertreatedbychemoradiotherapyandbrachytherapy
AT schlumbergermartin increasedbonemarrowsuvmaxon18ffdgpetisassociatedwithhigherpelvictreatmentfailureinpatientswithcervicalcancertreatedbychemoradiotherapyandbrachytherapy
AT haiemederchristine increasedbonemarrowsuvmaxon18ffdgpetisassociatedwithhigherpelvictreatmentfailureinpatientswithcervicalcancertreatedbychemoradiotherapyandbrachytherapy
AT chargaricyrus increasedbonemarrowsuvmaxon18ffdgpetisassociatedwithhigherpelvictreatmentfailureinpatientswithcervicalcancertreatedbychemoradiotherapyandbrachytherapy
AT deutscheric increasedbonemarrowsuvmaxon18ffdgpetisassociatedwithhigherpelvictreatmentfailureinpatientswithcervicalcancertreatedbychemoradiotherapyandbrachytherapy